User profiles for J. van der Hilst

Jeroen VAN DER HILST

UHasselt
Verified email at uhasselt.be
Cited by 2868

Hereditary periodic fever and reactive amyloidosis

JCH Van der Hilst, A Simon, JPH Drenth - Clinical and experimental …, 2005 - Springer
Hereditary periodic fever syndromes (HPF) are a group of diseases characterised by recurrences
of fever and inflammation separated by symptom-free intervals. Familial Mediterranean …

Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature

JCH van der Hilst, M Moutschen… - … : Targets and Therapy, 2016 - Taylor & Francis
Introduction In 5%–10% of patients with familial Mediterranean fever (FMF), colchicine is not
effective in preventing inflammatory attacks. Another 5%–10% of patients are intolerant to …

[HTML][HTML] Canakinumab for the treatment of autoinflammatory recurrent fever syndromes

…, M Hofer, PJ Hashkes, J Van der Hilst… - … England Journal of …, 2018 - Mass Medical Soc
Background Familial Mediterranean fever, mevalonate kinase deficiency (also known as the
hyperimmunoglobulinemia D syndrome), and the tumor necrosis factor receptor–associated …

Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome

JCH van der Hilst, EJ Bodar, KS Barron, J Frenkel… - Medicine, 2008 - journals.lww.com
The hyperimmunoglobulinemia D and periodic fever syndrome (HIDS), one of the autoinflammatory
syndromes, is caused by mutations in the gene coding for mevalonate kinase (MVK). …

Mimickers of urticaria: urticarial vasculitis and autoinflammatory diseases

MDP Davis, JCH van der Hilst - The Journal of Allergy and Clinical …, 2018 - Elsevier
… Author links open overlay panel Mark DP Davis MD a , Jeroen CH van der Hilst MD, PhD
b … JP Drenth, JW van der Meer … JC van der Hilst, A. Simon, JP Drenth …

[HTML][HTML] Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial

…, J Van Laethem, S Anguille, J van Der Hilst… - The Lancet …, 2021 - thelancet.com
Background Infections with SARS-CoV-2 continue to cause significant morbidity and mortality.
Interleukin (IL)-1 and IL-6 blockade have been proposed as therapeutic strategies in …

[PDF][PDF] Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model.

…, JCH van der Hilst, JPH Drenth, JWM van der Meer… - 2005 - repository.ubn.ru.nl
BACKGROUND: Hyper-IgD and periodic fever syndrome (HIDS) is an hereditary autoinflammatory
syndrome, characterised by recurrent inflammatory attacks. Treatment of HIDS is …

Beneficial response to interleukin 1 receptor antagonist in traps

…, JCH van der Hilst, JWM van der Meer… - The American journal …, 2004 - amjmed.com
Journal of Medicine, Malouf et al discussed the diagnostic challenge of mycotic aneurysms (1).
We consider this to be a very important issue. We recently observed a case of abdominal …

[HTML][HTML] Risk factors for mortality in hospitalized patients with COVID-19 at the start of the pandemic in Belgium: a retrospective cohort study

K van Halem, R Bruyndonckx, J van der Hilst… - BMC infectious …, 2020 - Springer
Background Belgium was among the first countries in Europe with confirmed coronavirus
disease 2019 (COVID-19) cases. Since the first diagnosis on February 3rd, the epidemic has …

Beneficial response to anakinra and thalidomide in Schnitzler's syndrome

…, EJ Bodar, A Simon, JCH van der Hilst… - Annals of the …, 2006 - ard.bmj.com
… JCH van der Hilst, … Bodar EJ, Van der Hilst JCH, Drenth JPH, Van der Meer JWM, Simon
A. Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: …